WO2015115545A1 - Procédé pour évaluer une métastase ou un risque de récidive d'un cancer du sein - Google Patents

Procédé pour évaluer une métastase ou un risque de récidive d'un cancer du sein Download PDF

Info

Publication number
WO2015115545A1
WO2015115545A1 PCT/JP2015/052522 JP2015052522W WO2015115545A1 WO 2015115545 A1 WO2015115545 A1 WO 2015115545A1 JP 2015052522 W JP2015052522 W JP 2015052522W WO 2015115545 A1 WO2015115545 A1 WO 2015115545A1
Authority
WO
WIPO (PCT)
Prior art keywords
base
seq
dna
breast cancer
nos
Prior art date
Application number
PCT/JP2015/052522
Other languages
English (en)
Japanese (ja)
Inventor
哲 清水
洋平 宮城
敬 大津
光江 齊藤
林崎　良英
昌可 伊藤
英哉 川路
寛子 大宮
Original Assignee
地方独立行政法人神奈川県立病院機構
学校法人順天堂
国立研究開発法人理化学研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 地方独立行政法人神奈川県立病院機構, 学校法人順天堂, 国立研究開発法人理化学研究所 filed Critical 地方独立行政法人神奈川県立病院機構
Priority to JP2015560010A priority Critical patent/JPWO2015115545A1/ja
Publication of WO2015115545A1 publication Critical patent/WO2015115545A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Definitions

  • the present invention relates to a method for evaluating the risk of breast cancer metastasis or recurrence at the molecular level.
  • Luminal A Luminal A
  • Luminal B HER2-positive and Triple-negative (TN)
  • TN Triple-negative
  • Mammaprint (Agendia-DNA chip research institute) has been put into practical use as a test for research (Patent Document 1), which roughly measures postoperative recurrence risk in patients with early breast cancer using a 70-gene signature. Therefore, there is a demand for more detailed diagnosis and prediction of recurrence according to the presence or absence of chemotherapy and the type of breast cancer.
  • RNA-seq Non-Patent Document 1
  • CAGE Cap Analysis Gene Expression: Non-Patent Document 2
  • the CAGE method has a feature that the activity of the transcription start site can be comprehensively quantified by selecting a long capped RNA such as mRNA and sequencing the 5 'end randomly and in large quantities.
  • the present invention relates to providing a method for objectively and rapidly discriminating the presence / absence of the drug effect of chemotherapy in breast cancer, the risk of recurrence, or the possibility of metastasis with high accuracy.
  • the present inventors extract RNA from breast cancer tissues obtained by surgery with or without recurrence, and those with or without lymph node metastasis, and use the CAGE analysis method for transcription initiation region (Transcript).
  • TSS Start Site
  • the expression level of DNA containing a specific transcription start region is significantly different between the two groups, and using this as an index, “with relapse” And “no recurrence”, “with lymph node metastasis” and “without lymph node metastasis”.
  • the present invention relates to the following 1) to 4).
  • the method includes measuring the expression level of one or more expression products of DNA including a transcription initiation region, A method to assess the risk of recurrence.
  • It contains an oligonucleotide that specifically hybridizes with the transcription product of DNA or an antibody that recognizes the translation product of DNA, and is used for testing for evaluating the risk of metastasis or recurrence of breast cancer used in the method of 1) kit.
  • Use of one or more expression products of DNA containing a transcription initiation region as a marker for evaluating the risk of breast cancer metastasis or recurrence.
  • the drug effect prediction of chemotherapy and the presence or absence of recurrence can now be determined quickly and accurately, and high-risk patients can be identified with high accuracy.
  • a treatment strategy that is appropriate for individual breast cancer, such as aggressive chemotherapy for breast cancer that is effective for chemotherapy, and preoperative surgery and change of regimen for breast cancer that is not effective for chemotherapy.
  • the TN type has a lower response rate and higher recurrence rate than the other three types, but by using the method of the present invention, the TN type has a biological basis. This will open the way to the selection of better treatments and the development of new treatments.
  • the same or higher classification can be objectively performed by using the present invention without depending on subjectivity of experts such as pathologists and clinical technologists who have been trained. Therefore, it can be suitably used for a test (POCT: Point of Care Testing) performed by a medical worker alongside a patient from collection to analysis of a patient specimen.
  • POCT Point of Care Testing
  • breast cancer means a carcinoma that occurs in breast tissue.
  • Breast cancer is classified into four types, Luminal A, Luminal B, HER2-positive, and Triple-negative (TN), based on biological characteristics, and is divided into 0 to 4 stages depending on the stage.
  • metastasis means that breast cancer grows in lymph nodes and other organs, and the evaluation of metastasis is the presence or absence of metastasis or the ability to metastasize (the ability of breast cancer to metastasize and proliferate). It means to evaluate or measure the presence or absence.
  • Preferable examples include evaluating or measuring lymph node metastasis.
  • risk of recurrence means the likelihood of recurrence.
  • Relapse refers to a case in which a malignant tumor reappears at the same site after the tumor has been removed from the living body for a certain period of time, and when tumor cells are separated from the primary lesion and carried to a distant tissue where they proliferate autonomously. Refers to cases. Whether or not recurrence occurs depends on the proliferative ability, viability, and migration ability of tumor cells.
  • the evaluation method of the present invention is particularly useful for evaluating the risk of recurrence in patients who have not received neoadjuvant chemotherapy and in patients who have been treated with TN type and who have not received neoadjuvant chemotherapy.
  • the TN type disease type is an estrogen receptor negative, progesterone receptor negative and HER2 negative type in immunopathological examination
  • the HER2-positive type disease type is HER2 in immunopathological examination. Is a type that is overexpressed.
  • Stage 2a refers to a tumor having a maximum tumor diameter of 2 cm or less and 1 to 3 regional lymph node metastases (including at least one tumor having a maximum diameter exceeding 2 mm), or a maximum tumor diameter of 2 cm. 2b or less and no regional lymph node metastasis.
  • 2b means that the maximum diameter of the tumor exceeds 2 cm and is 5 cm or less and 1 to 3 regional lymph node metastases (maximum diameter is 0.2 mm or more) Or a tumor with a maximum diameter of more than 5 cm and no regional lymph node metastasis.
  • the biological sample used in the present invention is a breast cancer tissue separated from a breast cancer patient to be evaluated.
  • the biological sample is appropriately prepared and processed for use in measurement.
  • an RNA extract is prepared, and when the sample is subjected to measurement at the protein level, a protein extract is prepared.
  • Any known method can be used as a method for extracting RNA from a biological sample. Specific examples include Ambion RiboPure kit manufactured by Life Technologies, miRNeasy manufactured by Qiagen, and RNeasy manufactured by Qiagen. Among these, the miRNeasy kit manufactured by Qiagen is preferably used.
  • nucleic acid or “polynucleotide” means DNA or RNA.
  • DNA includes not only double-stranded DNA but also single-stranded DNAs comprising a sense strand and an antisense strand constituting the DNA. Accordingly, the DNA includes double-stranded genomic DNA, single-stranded cDNA, single-stranded DNA having a sequence complementary to the DNA, and the like.
  • RNA includes any of total RNA, mRNA, rRNA, and synthetic RNA.
  • the transcription product of DNA consisting of the nucleotide sequence shown in SEQ ID NOs: 1 to 199 is 1) preoperative chemistry as shown in the Examples.
  • the RNA transcriptional activity of the specimens 1) to 4) is obtained from the clinical specimen-derived profile group obtained from “with recurrence” or “with metastasis”, “without recurrence” or “without metastasis”.
  • the R / Bioconductor edgeR package (Bioinformatics. 2010 Jan 1; 26 (1): 139-40) was used for differential analysis between the clinical specimen-derived profile groups, and a 5% FDR (false discovery rate) was set as a threshold. It has been extracted.
  • the expression product (referred to as “the expression product of the present invention”) (referred to as “the DNA containing the starting point”) (or encoded thereby) can be a biomarker for assessing the risk of breast cancer metastasis or recurrence.
  • Expression product of DNA containing the transcription start site in SEQ ID NOs: 1-32 A biomarker for evaluating the risk of recurrence in breast cancer patients who have not undergone preoperative chemotherapy.
  • the DNA expression product containing the transcription start point in SEQ ID NOs: 1 to 5 is a marker whose expression level increases when the risk of recurrence is high
  • the DNA expression product containing the transcription start point in SEQ ID NOs: 6 to 32 is It is a marker that decreases the expression level when the risk of recurrence is high.
  • the DNA expression product is a marker that increases the expression level when the risk of recurrence is high.
  • the DNA expression product containing the transcription start point in SEQ ID NOs: 108 to 164 is a marker whose expression level increases when the possibility of lymph node metastasis is high, and the DNA containing the transcription start point in SEQ ID NOs: 165 to 177
  • the expression product is a marker that decreases the expression level when the possibility of lymph node metastasis is high.
  • a biomarker for evaluating lymph node metastasis in breast cancer patients whose expression product type of DNA containing the transcription start site in SEQ ID NOs: 178 to 199 is HER2-positive type and stage is 2a or 2b.
  • the DNA expression product containing the transcription start point in SEQ ID NOs: 178 to 184 is a marker whose expression level increases when the possibility of lymph node metastasis is high, and the DNA containing the transcription start point in SEQ ID NOs: 185 to 199
  • the expression product is a marker that decreases the expression level when the possibility of lymph node metastasis is high.
  • the “transfer start region” refers to a region including a transfer start point.
  • the transcription start point from a specific promoter is not limited to a single base, and may be a base present at a plurality of positions downstream of the promoter on the genome.
  • a region including a plurality of these transfer start points is referred to as a transfer start region in this specification. More specifically, the transfer start area is an area between the transfer start point located on the most 5 ′ side and the transfer start point located on the most 3 ′ side among the plurality of transfer start points.
  • each of the base sequences represented by SEQ ID NOs: 1 to 199 has a 5 ′ end corresponding to a region defined at both ends by the base at position 1 (5 ′ end) and the 101st base from the 3 ′ end. This is a base region to be formed.
  • each of the base sequences represented by SEQ ID NOs: 1 to 199 shows a transcription start region and 100 bases following the transcription start point located on the most 3 ′ side in the transcription start region.
  • such a transcription initiation region is also referred to as “a transcription initiation region represented by SEQ ID NOs: 1 to 199”.
  • the positions of the transcription start regions shown in SEQ ID NOs: 1 to 199 on the genome, and related gene information, etc. are described in Tables 1-1 to 1-2, Tables 2-1 to 2-3, and Tables 3-1 to 3 below. -3 and Table 4.
  • the DNA for which the expression level of the expression product is measured is the base sequence at any position (transcription start point) in the transcription start region and the downstream 1 in the base sequence represented by SEQ ID NOs: 1 to 199. It is DNA consisting of a base sequence of bases or more.
  • the number of bases in the downstream base sequence may be any number that can identify the expression product. Examples of the number of bases include 1 base or more, 5 bases or more, 10 bases or more, 15 bases or more, 20 bases or more, 25 bases or more, 30 bases or more, 40 bases or more, 50 bases or more.
  • the said base number 10 bases or less, 15 bases or less, 20 bases or less, 25 bases or less, 30 bases or less, 40 bases or less, 50 bases or less, 100 bases or less are mentioned, for example.
  • the downstream base is not particularly necessary in the case of measurement by the CAGE method, but in the case of measurement by hybridization or PCR, any part up to about 100 bases downstream is targeted in order to ensure the accuracy.
  • the DNA has a length of at least 20 bases out of DNA consisting of the transcription start region and 100 bases downstream from it, there is a high probability that it can be identified even in an experimental system for the entire genome.
  • the DNA also includes DNA having a base sequence substantially identical to the base sequence of the DNA as long as the expression product can be a biomarker for evaluating the risk of breast cancer metastasis or recurrence.
  • Such expression products of the present invention can be used to assess the risk of breast cancer metastasis or recurrence by appropriately combining one or more of the expression products and grasping the expression level.
  • the threshold values shown in Tables 5 to 7 below are set, DNA that can be classified with specificity 100% and sensitivity 100%, that is, DNA that can be reliably discriminated only with one expression level, The following are mentioned.
  • SEQ ID NO: 194 SEQ ID NO: 187, SEQ ID NO: 186, SEQ ID NO: 192, or SEQ ID NO: 193 in the evaluation of lymph node metastasis of a breast cancer patient whose disease type is HER2-positive type and stage is 2a or 2b
  • a suitable combination in the case where at least two DNA expression products are used that is, for all two combinations selected from the above transcription start regions, these expression levels are used as explanatory variables, and recurrence related to the transcription start region extraction sample.
  • a logistic regression model that estimates the presence or absence of lymph node metastasis is constructed, and the DNA shown in Tables 8 to 11 below can be classified as 100% specificity and 100% sensitivity for both the transcription start region extraction sample and the verification sample.
  • the expression products are listed respectively. For the purpose of further improving the accuracy, these can be used in combination of two sets or three sets or more as appropriate.
  • the expression products of these two DNAs may be combined with the expression products of DNAs other than those shown as the combination among the DNAs containing the transcription start sites in SEQ ID NOs: 1 to 199, May be combined with DNA expression products consisting of any other base sequence within a range that can contribute to the evaluation of the present invention.
  • the expression product of the present invention includes a transcription product and a translation product expressed from the DNA.
  • Specific examples of the transcription product include RNA generated by transcription from the DNA, preferably mRNA.
  • Specific examples of the translation product include a protein encoded by the RNA.
  • the protein expressed from the DNA containing the transcription start sites in SEQ ID NO: 112 and SEQ ID NO: 196 is “HLA-DQA1” (Major Histocompatibility Complex, Class II, DQ Alpha 1; UniProtKB / Swiss-Prot: DQA1_HUMAN, P01909).
  • the target of the measurement or detection of the expression product is cDNA artificially synthesized from the RNA, DNA encoding the RNA, protein encoded by the RNA, molecule interacting with the protein, and interaction with the RNA. Also included are molecules that act or molecules that interact with the DNA.
  • molecules that interact with RNA, DNA or protein DNA, RNA, protein, polysaccharide, oligosaccharide, monosaccharide, lipid, fatty acid, and their phosphates, alkylated products, sugar adducts, and the like, and Any of the above-mentioned complexes can be mentioned.
  • the expression level comprehensively means the expression level and activity of the expression product.
  • RNA, cDNA or DNA is targeted as a method for measuring the expression level, nucleic acid amplification represented by PCR method, real-time RT-PCR method, SmartAmp method, LAMP method, etc. using DNA hybridizing to these primers Method, hybridization method using nucleic acids that hybridize to these as probes (DNA chip, DNA microarray, dot blot hybridization, slot blot hybridization, northern blot, hybridization, etc.), method for determining the base sequence, or these You can choose from a combination of methods.
  • the probe or primer used for the measurement that is, the primer for specifically recognizing and amplifying the expression product (transcription product) of the present invention or the nucleic acid derived therefrom, or the RNA or the nucleic acid derived therefrom is specific.
  • “specifically recognize” means that, for example, in the Northern blot method, substantially only the expression product (transcription product) of the present invention or a nucleic acid derived therefrom can be detected.
  • the detection product or product can be determined to be the transcription product or a nucleic acid derived therefrom so that only the nucleic acid is produced.
  • DNA comprising a base sequence represented by SEQ ID NOs: 1 to 199 or an oligonucleotide containing a certain number of nucleotides complementary to its complementary strand can be used.
  • the “complementary strand” refers to the other strand with respect to one strand of double-stranded DNA comprising A: T (U in the case of RNA) and G: C base pairs.
  • “complementary” is not limited to the case where the certain number of consecutive nucleotide regions are completely complementary sequences, preferably 80% or more, more preferably 90% or more, and still more preferably 95% or more. What is necessary is just to have the identity on arrangement
  • the identity of the base sequence can be determined by the algorithm such as BLAST. When such an oligonucleotide is used as a primer, it only needs to be capable of specific annealing and chain extension, and is usually 10 bases or more, preferably 15 bases or more, more preferably 20 bases or more, and for example 100 bases or less. Those having a chain length of preferably 50 bases or less, more preferably 35 bases or less are mentioned.
  • oligonucleotide when used as a probe, it only needs to be capable of specific hybridization, and has at least part or all of the sequence of DNA (or its complementary strand) consisting of the base sequence represented by SEQ ID NOs: 1 to 199, for example, A chain length of 10 bases or more, preferably 15 bases or more and, for example, 100 bases or less, preferably 50 bases or less, more preferably 25 bases or less is used.
  • the “oligonucleotide” may be DNA or RNA, and may be synthesized or natural.
  • the probe used for hybridization is usually labeled.
  • the probe DNA is first labeled with a radioisotope, a fluorescent substance, etc., and then the obtained labeled DNA is transferred to a nylon membrane or the like according to a conventional method. Hybridize with RNA. Thereafter, a method of detecting and measuring a signal derived from the labeled product of the formed duplex of labeled DNA and RNA can be used.
  • cDNA is prepared from RNA derived from a biological sample according to a conventional method so that the target expression product of the present invention (in this case, transcription product) can be amplified.
  • a pair of prepared primers (a normal strand that binds to the cDNA ( ⁇ strand) and a reverse strand that binds to the + strand) are hybridized therewith.
  • PCR is performed according to a conventional method, and the obtained amplified double-stranded DNA is detected.
  • detection of the amplified double-stranded DNA use a method of detecting the labeled double-stranded DNA produced by performing the above PCR using a primer previously labeled with RI, a fluorescent substance, etc. Can do.
  • nucleic acid derived from the expression product of the present invention (in this case, a transcription product) is immobilized on a support.
  • a nucleic acid derived from the expression product of the present invention (in this case, a transcription product) is immobilized on a support.
  • labeled cDNA or cRNA prepared from mRNA is bound on the microarray, and the label on the microarray is detected, whereby the mRNA expression level can be measured.
  • the nucleic acid immobilized on the array may be any nucleic acid that hybridizes specifically (ie, substantially only to the target nucleic acid) under stringent conditions.
  • the expression product of the present invention transcription
  • the product may be a nucleic acid having the entire sequence or a partial sequence.
  • the “partial sequence” includes a nucleic acid consisting of at least 15 to 25 bases.
  • stringent conditions can usually include washing conditions of about “1 ⁇ SSC, 0.1% SDS, 37 ° C.”, and more stringent hybridization conditions include “0.5 ⁇ SSC, 0.1%.
  • a more stringent hybridization condition a condition of “0.1 ⁇ SSC, 0.1% SDS, 65 ° C.” can be mentioned.
  • Hybridization conditions are described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Thrd Edition, Cold Spring Harbor Laboratory Press (2001) and the like.
  • Examples of the method for determining the base sequence include the CAGE method, the TSS-seq method, the RNA-seq method, the DGE method, and the SAGE method, and the CAGE method is preferable.
  • the expression level is measured using the CAGE method, it can be carried out in accordance with the method described in Examples below.
  • a protein ie, translation product
  • DNA containing the transcription start site in SEQ ID NOs: 1 to 199 a molecule that interacts with the protein, a molecule that interacts with RNA, or a molecule that interacts with DNA is measured.
  • protein chip analysis, immunoassay (for example, ELISA etc.), 1-hybrid method (PNAS 100, 12271-12276 (2003)) and 2-hybrid method (Biol. Reprod. 58, 302-311 (1998) )) Can be used and can be appropriately selected depending on the target.
  • an antibody against the expression product of the present invention in this case, a translation product
  • a biological sample an antibody against the expression product of the present invention
  • the polypeptide in the sample bound to the antibody is detected, and the level is detected.
  • This is done by measuring.
  • an antibody that binds to a primary antibody labeled with a radioisotope, a fluorescent substance, an enzyme, or the like as a secondary antibody is used. Labeling is performed, and signals derived from these labeling substances are measured with a radiation measuring instrument, a fluorescence detector or the like.
  • the antibody against the translation product may be a polyclonal antibody or a monoclonal antibody. These antibodies can be produced according to a known method. Specifically, the polyclonal antibody is used to immunize non-human animals such as rabbits by using a protein expressed and purified in E. coli or the like according to a conventional method, or by synthesizing a partial polypeptide of the protein according to a conventional method, It can be obtained from the serum of the immunized animal according to a conventional method.
  • a monoclonal antibody is obtained by immunizing a non-human animal such as a mouse with a protein expressed and purified in Escherichia coli according to a conventional method or a partial polypeptide of the protein, and fusing the obtained spleen cells with myeloma cells. It can be obtained from the prepared hybridoma cells.
  • a biological sample isolated from a patient is fixed in formalin by a conventional method, embedded in paraffin, sliced into tissue pieces, and pasted on a slide glass. It is preferably used as a section sample.
  • a biological sample separated from a patient can be frozen immediately, sliced into tissue pieces, attached to a slide glass, and fixed in formalin, and used as a section sample.
  • an enzyme-labeled antibody such as alkaline phosphatase or peroxidase can be used, but highly sensitive detection is performed using a three-step method such as ABC method or LSAB method, or the DAVision EnVision detection system. Is preferred.
  • the expression level of the expression product of the present invention in a biological sample derived from a cancer tissue separated from a breast cancer patient is measured, and the risk of breast cancer metastasis or recurrence is evaluated based on the expression level.
  • the expression level of the detected expression product of the present invention is evaluated by comparing it with a control level.
  • the “control level” refers to, for example, the expression level of the expression product in a cancer tissue isolated from a breast cancer patient without metastasis or recurrence or a normal tissue isolated from a breast cancer patient, or breast cancer has not developed.
  • the expression level of the expression product in a group of healthy people can be mentioned.
  • the expression level of the expression product of the target patient's cancer tissue is close to the expression level in a cancer tissue, normal tissue, or tissue derived from a healthy person isolated from a breast cancer patient who has not metastasized or recurred. If it falls within the range or is significantly higher (or lower) than the expression level, the patient's breast cancer can be evaluated as having no metastasis, low metastatic potential, or low risk of recurrence.
  • the risk of breast cancer metastasis or recurrence in the present invention can be evaluated by increasing / decreasing the expression level of the expression product of the present invention.
  • a control level for example, a standard value (threshold level) is set based on the expression level of the expression product derived from a normal tissue, a cancer tissue separated from a breast cancer patient without metastasis or recurrence, or a healthy tissue. It can be carried out by setting and comparing the expression level of the expression product in the patient-derived biological sample with a standard value (for example, the range of ⁇ 2SD is allowed). For example, when the expression level of the expression product in a patient-derived biological sample is higher (or lower) than a threshold level, the patient's breast cancer can be evaluated as having no metastasis, low metastatic potential, or low recurrence risk.
  • the risk of breast cancer metastasis or recurrence is evaluated based on the provided information in combination with other methods (CT, MRI, PET-CT, etc.) as necessary. If it is determined that there is a possibility of metastasis or recurrence, for example, chemotherapy and / or molecular targeted therapy, or radiation therapy or endocrine therapy can be performed. On the other hand, when it is determined that the possibility of metastasis or recurrence is low, it is considered unnecessary to perform these treatments.
  • the test kit for evaluating the risk of metastasis or recurrence of breast cancer of the present invention contains a test reagent for measuring the expression level of the expression product of the present invention in a biological sample separated from a patient.
  • a reagent for nucleic acid amplification or hybridization containing an oligonucleotide that specifically binds (hybridizes) to the expression product (transcription product) or the like of the present invention, or the expression product (translation product) of the present invention.
  • Oligonucleotides, antibodies and the like included in the kit can be obtained by known methods as described above.
  • the test kit can contain a labeling reagent, a buffer solution, a chromogenic substrate, a secondary antibody, a blocking agent, instruments and controls necessary for the test, and the like.
  • Example 1 Extraction and verification of transcription start region for discriminating between “with recurrence” and “without recurrence”, “with lymph node metastasis” and “without lymph node metastasis” in breast cancer
  • ⁇ 1 Breast cancer patients who received postoperative chemotherapy without preoperative chemotherapy> 10 samples for transcription start region extraction (no recurrence: 5 specimens, recurrence: 5 specimens) ⁇ Verification sample 4 specimens (no recurrence: 2 specimens, recurrence: 2 specimens) ⁇ 2: Breast cancer patients who are TN type and have not undergone preoperative chemotherapy> ⁇ 16 samples for extracting transcription start region (no recurrence: 14 specimens, recurrence: 2 specimens) ⁇ Verification sample 3 specimens (no recurrence: 2 specimens, recurrence: 1 specimen) ⁇ 3: Breast cancer patient whose disease type is TN type and stage is 2a or 2b> ⁇ 10 samples for extraction of transcription start region (no lymph node metastasis: 6 samples, lymph node metastasis: 4 samples) ⁇ Sample 3 sample for verification (no lymph node metastasis: 2 samples, with lymph node metastasis: 1 sample)
  • the extracted tissue pieces were appropriately frozen and stored at -80 ° C.
  • the preserved tissue pieces were wrapped in aluminum foil in a frozen state, further subjected to freezing treatment with liquid nitrogen, and then crushed with a rubber hammer.
  • the crushed sample was put in a 2 mL tube so as to be 50 mg or less, QIAzol manufactured by Qiagen was added and sealed, and crushed by osmosis treatment using TissueLyser manufactured by Qiagen.
  • RNA was prepared for RNA according to the attached protocol using miRNeasy mini kit manufactured by Qiagen.
  • the prepared RNA was measured for ultraviolet absorption (230, 260, 280 nm) with a spectrophotometer to calculate 260/230, 260/280 ratios, and the quality of the RNA was tested.
  • electrophoresis was performed using BioAnalyzer RNA nano chip manufactured by Agilent, and the RIN value indicating the degree of RNA degradation was calculated to test the degree of RNA degradation.
  • CAGE library preparation 5 ⁇ g of purified RNA was prepared, and unamplified untagged CAGE method (“Cell Engineering, separate volume, Advanced Method for Next-Generation Sequencer Purpose”, Juno Kanno, Satoshi Suzuki, Gakken Medical Shujunsha, 2012
  • the CAGE library was prepared by “Chapter 3“ Exhaustive promoter analysis (non-amplified CAGE method using Illumina sequencer) ”in“ Issue 19 Sep ”.
  • the purified RNA was subjected to reverse transcription reaction and purified, and then aldehyde was formed by participation of a ribose diol with sodium periodate, and biotin hydrazide was added to add biotin to the aldehyde group.
  • RNA / cDNA double strand biotinylated with avidin magnetic beads was bound to the bead surface, and the cDNA was released and recovered by RNase H digestion and heat treatment.
  • sequencing was performed using HiSeq 2500 manufactured by Illumina.
  • the standard conditions of AMPure XP (manufactured by Beckman Coulter) used for purification, buffer replacement, etc. in this step are conditions for recovering nucleic acids having a length of 100 bases or more in the case of double strands.
  • the CAGE library produced by this process using this is composed of double-stranded DNA having a chain length of 100 bases or more.
  • Example 2 Discrimination of the risk of metastasis or recurrence using HLA-DQA1 as a marker
  • Specimen Patients who received comprehensive consent before surgery (breast cancer patients whose disease type is TN type and stage is 2a or 2b) ) Surgical specimens that have been cryopreserved in 3) have been diagnosed as having recurrence (with lymph node metastasis during surgery) or without recurrence (no lymph node metastasis during surgery) 3 years after surgery It was used.
  • the present invention it is possible to objectively determine and predict the risk of breast cancer metastasis or recurrence by examining the primary lesion of breast cancer collected before or during surgery. This can be expected to contribute to the medical field and clinical laboratory field.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une technique pour évaluer objectivement, rapidement et avec une précision élevée la présence ou l'absence de l'effet d'un médicament, le risque d'une récidive ou la possibilité d'une métastase lors d'une chimiothérapie d'un cancer du sein. L'invention concerne un procédé pour évaluer la métastase d'un cancer du sein ou le risque d'une récidive d'un cancer du sein chez un patient souffrant d'un cancer du sein, ledit procédé comprenant une étape de mesure du niveau d'expression d'au moins un produit d'expression de l'ADN contenant un domaine d'initiation de transcription dans un échantillon biologique dérivé d'un tissu cancéreux prélevé sur le patient.
PCT/JP2015/052522 2014-01-31 2015-01-29 Procédé pour évaluer une métastase ou un risque de récidive d'un cancer du sein WO2015115545A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015560010A JPWO2015115545A1 (ja) 2014-01-31 2015-01-29 乳がんの転移又は再発リスクの評価方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014017946 2014-01-31
JP2014-017946 2014-01-31

Publications (1)

Publication Number Publication Date
WO2015115545A1 true WO2015115545A1 (fr) 2015-08-06

Family

ID=53757115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/052522 WO2015115545A1 (fr) 2014-01-31 2015-01-29 Procédé pour évaluer une métastase ou un risque de récidive d'un cancer du sein

Country Status (2)

Country Link
JP (1) JPWO2015115545A1 (fr)
WO (1) WO2015115545A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007267692A (ja) * 2006-03-31 2007-10-18 Sysmex Corp 乳がんのリンパ節転移マーカー、プライマ及びこのマーカーを用いた乳がんのリンパ節転移判定方法
JP2007530075A (ja) * 2004-04-23 2007-11-01 エグザジェン ダイアグノスティクス インコーポレイテッド 乳がんの予後診断のための組成物および方法
JP2013099253A (ja) * 2010-03-11 2013-05-23 Intec Systems Institute Inc 肺癌または子宮頸癌の診断マーカー

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530075A (ja) * 2004-04-23 2007-11-01 エグザジェン ダイアグノスティクス インコーポレイテッド 乳がんの予後診断のための組成物および方法
JP2007267692A (ja) * 2006-03-31 2007-10-18 Sysmex Corp 乳がんのリンパ節転移マーカー、プライマ及びこのマーカーを用いた乳がんのリンパ節転移判定方法
JP2013099253A (ja) * 2010-03-11 2013-05-23 Intec Systems Institute Inc 肺癌または子宮頸癌の診断マーカー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN L.H. ET AL.: "Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan .", PLOS ONE, vol. 6, no. 11, 2011, pages E28222, XP055065593 *
KOJI SENUMA ET AL.: "PATHOLOGICAL THERAPEUTIC EFFECTS OF PREOPERATIVE SYSTEMIC CHEMOTHERAPY ASSOCIATED WITH BIOMARKERS FOR PRIMARY BREAST CANCER", JUNTENDO MEDICAL JOURNAL, vol. 59, no. 3, 2013, pages 251 - 259 *
MUSTACCHI G. ET AL.: "Identification and validation of a new set of five genes for prediction of risk in early breast cancer.", INT.J.MOL.SCI., vol. 14, no. 5, 2013, pages 9686 - 9702, XP055090028 *

Also Published As

Publication number Publication date
JPWO2015115545A1 (ja) 2017-03-23

Similar Documents

Publication Publication Date Title
US9249467B2 (en) Bladder cancer detection composition, kit and associated methods
JP6285009B2 (ja) 前立腺ガンの予後の検知及び判定のための組成物及び該検知及び判定方法
US20220093251A1 (en) Novel biomarkers and diagnostic profiles for prostate cancer
TWI682034B (zh) 用於評估子宮內膜癌的發展風險或診斷子宮內膜癌的方法
US10233502B2 (en) Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer
CN110229899B (zh) 用于结直肠癌早期诊断或预后预测的血浆标记物组合
KR102096498B1 (ko) 대장암 진단 또는 재발 예측을 위한 마이크로RNA-4732-5p 및 이의 용도
JP6711968B2 (ja) 子宮体がんのリンパ節転移能の評価方法
JP6949315B2 (ja) 肺扁平上皮癌と肺腺癌の鑑別評価方法
US11732305B2 (en) Method and kit for diagnosing early stage pancreatic cancer
WO2015115544A1 (fr) Procede d'evaluation du risque de metastase ou de recurrence d'un cancer du colon
KR102384992B1 (ko) 대장암 환자의 연령 특이적 바이오마커 및 이의 용도
KR102096499B1 (ko) 대장암 진단 또는 재발 예측을 위한 마이크로rna-3960 및 이의 용도
US20160304961A1 (en) Method for predicting the response to chemotherapy treatment in patients suffering from colorectal cancer
WO2015115545A1 (fr) Procédé pour évaluer une métastase ou un risque de récidive d'un cancer du sein
EP3321683A1 (fr) Procédé d'évaluation de potentiel métastatique dans les ganglions lymphatiques du cancer de l'endomètre
WO2015105191A1 (fr) Méthode d'évaluation des lésions lymphadénopathiques
WO2022196750A1 (fr) Marqueur d'accompagnement pour procédé d'évaluation de la capacité de métastases d'un ganglion lymphatique du cancer de l'endomètre
KR102259708B1 (ko) 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커
KR102416614B1 (ko) 방사선 저항성 지표 단백질 및 이의 검출방법
CN114746551A (zh) 大肠癌诊断用标志物、辅助大肠癌的诊断的方法、收集数据以用于大肠癌诊断的方法、大肠癌的诊断试剂盒、大肠癌治疗药物、大肠癌的治疗方法、大肠癌的诊断方法
BG67180B1 (bg) Метод и кит за откриване на онкофузионен протеин

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15742701

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015560010

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15742701

Country of ref document: EP

Kind code of ref document: A1